S-1: CytoDyn Files S-1 Registration for Resale of Up to 141 Million Shares

CytoDyn Inc. has filed an S-1 registration statement with the SEC to allow selling stockholders to resell up to 141,019,099 shares of common stock, including shares underlying warrants.

Summary

• CytoDyn Inc., a clinical-stage biotechnology company, has filed a Form S-1 registration statement with the SEC.
• The filing covers the resale of up to 35,792,347 shares of common stock and 105,226,752 shares underlying certain warrants by selling stockholders.
• The company will not receive any proceeds from the sale of shares by the selling stockholders, but may receive proceeds from the cash exercise of warrants.
• The company's common stock is quoted on the OTCQB under the symbol CYDY, with a closing price of $0.18 on February 1, 2024.
• The registration statement includes information about the company's business, financial condition, risk factors, and management.
• CytoDyn's core areas of development are HIV, MASH, and solid tumors in oncology.
• The company is currently under a full clinical hold by the FDA related to its proposed HIV clinical trial protocol.
• The company is also working on developing a longer-acting version of leronlimab and exploring potential business opportunities for solid tumors in oncology.
• The company faces significant financial challenges, including low cash reserves and a history of operating losses.
• The company's auditor has issued a going concern opinion, indicating substantial doubt about its ability to continue as a going business.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation with a going concern warning and regulatory hurdles, overshadowing any potential positives. The company's future is highly dependent on overcoming these challenges.

Positives

• The company is actively seeking the removal of the clinical hold imposed by the FDA.
• CytoDyn is pursuing research and development of longer-acting molecules for HIV treatment and prevention.
• The company is evaluating opportunities for pre-clinical studies in solid tumors in oncology.
• The company has a partnership with Albert Einstein College of Medicine and Montefiore Medical Center to study leronlimab in glioblastoma multiforme.
• The company has a joint development agreement with a third-party generative AI drug discovery and development company to develop one or more longer-acting molecules.

Negatives

• The company's cash reserves are extremely low, requiring substantial additional financing.
• CytoDyn has a history of significant operating losses and expects to continue incurring losses.
• The company's auditor has issued a going concern opinion, indicating substantial doubt about its ability to continue as a going business.
• The company is currently under a full clinical hold by the FDA related to its proposed HIV clinical trial protocol.
• Samsung has notified the company of its intent to terminate manufacturing agreements.
• The company has written off the value of its pre-launch inventories of leronlimab and related raw materials.

Risks

• The company's ability to raise additional capital is uncertain.
• The company is substantially dependent on the success of leronlimab.
• The company faces intense competition in the biopharmaceutical industry.
• The company is dependent on third parties for clinical trials and manufacturing.
• The company's common stock is classified as penny stock and trading may be restricted.
• The trading price of the company's common stock has been and could remain volatile.
• The company is subject to oversight by the SEC, FDA, and other regulatory agencies.
• The company faces risks and uncertainties related to litigation and other claims.

Future Outlook

The company plans to continue to engage in research and development activities related to leronlimab and a new or modified longer-acting therapeutic for multiple indications and expects to incur significant research and development expenses in the future, primarily related to its regulatory compliance, including seeking the lifting of the FDAs clinical hold related to the Companys recently submitted protocol, performing additional clinical trials, and seeking regulatory approval of its product candidate for commercialization.

Management Comments

• Dr. Jacob P. Lalezari is responsible for leading the Companys corporate and product development, with a focus on short-term clinical development and related fundraising.

Industry Context

The biopharmaceutical industry is intensely competitive, and CytoDyn's future success depends on its ability to demonstrate and maintain a competitive advantage with respect to the design, development, and commercialization of product candidates.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• However, it mentions that the company competes against large pharmaceutical and biotechnology companies and smaller companies collaborating with larger firms.
• These competitors generally have substantially greater financial resources and experience in drug development, clinical trials, and commercialization.

Management Changes

Legal Proceedings

• The company is a party to various legal proceedings, including securities class action lawsuits, shareholder derivative lawsuits, and investigations by the SEC and DOJ.
• The company is also involved in a dispute with Amarex Clinical Research LLC.

Related Party Transactions

• Lalezari Medical Corp., dba Quest Clinical Research (Quest), owned by Dr. Lalezari, the Companys current CEO, was one of several clinical locations for the Companys past COVID19 clinical trials.
• The Company entered into a Clinical Trial Agreement (CTA) with Quest in relation to said clinical trials.
• Since June 1, 2021, the Company has paid Quest approximately $1.2 million for its services in conducting clinical trials of leronlimab.
• As of February 1, 2024, the outstanding balance owed by the Company to Quest was approximately $0.4 million.

Stakeholder Impact

• Shareholders face significant risks due to the company's financial challenges and regulatory hurdles.
• Employees may experience uncertainty due to the company's financial instability and potential restructuring.
• Customers (potential patients) may face delays in accessing leronlimab due to the clinical hold and manufacturing issues.
• Suppliers and creditors face the risk of non-payment due to the company's low cash reserves.
• The company's ability to meet its debt and other payment obligations is uncertain.

Next Steps

• Seeking the removal of the clinical hold imposed by the FDA.
• Proceeding toward conducting a Phase II study evaluating the effects of leronlimab on chronic immune activation and inflammation in cisgender men and women and transgender women living with HIV.
• Pursuing research and development of longer-acting molecules, including for the treatment and/or prevention of HIV.
• Evaluating whether to conduct a combination pre-clinical study or monotherapy Phase 2b/3 clinical trial in MASH.
• Evaluating opportunities for pre-clinical studies in solid tumors in oncology and publishing data from previously conducted studies.
• Resolving legal, regulatory, and financial matters.

Key Dates

Keywords

leronlimab, CytoDyn, clinical hold, MASH, HIV, oncology, warrants, S-1, SEC, biotechnology, clinical trials, FDA, common stock, registration statement